Disclosed are messenger RNA molecules and related compositions incorporating a 4"-thio modification in the furanosering of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4"-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.
